Duloxetine, a serotonin and norepinephrine reuptake inhibitor, reduces daily OFF time in Parkinson’s disease
Objective: To evaluate efficacy of duloxetine on motor symptoms in Parkinson's disease (PD) patients with wearing-off in an open label trial. Background: Duloxetine, a serotonin…Neuroprotective and antidepressant-like effects of the endogenous amines from tetrahydroisoquinoline group TIQ and 1MeTIQ in the animal model of depressive disorder: Behavioral and neurochemical studies in the rat
Objective: For the purpose of estimation neuroprotective and antidepressant-like effects of the endogenous amines 1,2,3,4-tetrahydroisoquinoline (TIQ) and its close methyl derivative, 1-methyl-1,2,3,4-tetrahydroisoquinoline (1MeTIQ) in the…Prevalence of depression in Parkinson’s disease patients
Objective: The objective of this study was to determine the prevalence of depression in PD patients taking into account the different settings and different diagnostic…Effects of antidepressants on gait parameters in Parkinson’s disease
Objective: To compare GAITRite parameters between PD patients on antidepressants with patients who were not on any psychotropic. Background: PD patients have an increased risk…The effects of fluvoxamine maleate in a post-natal stress rat model of neurodegeneration
Objective: In this study, we investigated whether treatment of anxiety-like symptoms with Fluvoxamine maleate alleviates the neurotoxic effects of 6-OHDA in a Parkinsonian rat model.…Impaired hippocampal neurogenesis associates with serotonergic axonal degeneration in transgenic rat and mouse models of Parkinson’s disease
Objective: To evaluate the impact of α-synuclein accumulation on the hippocampal serotonergic system and hippocampal plasticity in two different α-synuclein expressing rodent models. Background: Parkinson's…